of creation call, quarter, during I everyone an that earnings outlined commercial an on our you our followed thank us update for XXXX providing first four first fourth of call. in the update Garth, Thanks, by quarter joining by the quarter value data each progress we prepared GI's start drivers today Modus for I'll specifically, first our overview on which include Upper will to financial clinical call the quarter. to GI of At I'll FDA recently Pure-Vu our performance remarks, take strategic end your the innovation, provide the partnerships. then an reimbursement, Andrew our for questions. system, and ask and cleared product open more
relates To market conditions are team specific target multi for evaluations progress, customer result, to acceptance pleased focus as to As which larger hospitals, dozen US cultivate to conducted execute a QX strategy I'm are our as system have impacts our it relationships and that commercial Pure-Vu important academic of centers due building more we varying steadily on two colonoscopy. in And particularly hospitals. continues These systems. COVID-XX. medical our awareness, date, than health improving most of report utilization market to product that site speeds, at of progressed to we've part prominent are evaluations of hospital proprietary at
taken the As a our than planned. commercialization longer initial phase of result, has
I in growing. However, Pure-Vu that am is pleased interest
has receiving our customers the system, feedback technology and existing regarding more Importantly, hospitals commercial users which prospective requests highly positions from believe We're by very future inbound success. well in physicians Pure-Vu us we for evaluating and positive. been interested
at US Our key been strategy primarily leading on initial prominent focused hospital opinion systems. GIs has
our including marketing, on growing we've of year, effort with compendium clinical are studies, our as this last online through digital platforms. creation physicians, in podcast the our case one as which social series, available the GI During well supported and interviews also of investments Pure-Vu other media through one website
regional to sales pipeline, our of terms team expanding community IBM. hospitals, our and is In its outreach
in Maryland. Methodist Texas, restarted Houston as we in at QX, and of the as largest evaluations community Hospital, one completed Hospital hospitals example, well both Sinai For in
incremental third Notably, quarter this performance represented consecutive indicators first of quarter last of terms revenue a delivered we of key revenue in compared to the XXXX, XX% in our growth. In increase quarter.
GI additional of increase we we are on targeted of are large Pure-Vu We now for we accounts. Pure-Vu sleeves with market site in evaluations conducting us at steady to this adjustable hospitals very numbers the opportunity purchases of comparison paid part well this of at signed minimum agreements, We the access which to attribute the the for second product to training in in Pure-Vu hospitals, to volume Pure-Vu four the as conducted physicians as as still and are to workstation. procedures rebound our in most quite half quarterly revenue regained procedures XXXX. quarter, US, US both major While require see modest single-use as relative return encouraged have of progress use
sites negotiating in are additional expect close that as second currently We agreements, to such key quarter. purchases the we with capital as well
bit volume these a expand me further committed on Let agreements specifically.
agreements adopter recurring us reasonably customer revenues First, these quarter. with sleeve predictable early provide each
we provide the agreements margins, as on the return these workstation. list sleeves typically for for strong use pricing gross command of in Second,
the Finally, with balance sites, levels committed aim continue of expect to through within we each the train additional minimum grow requirements. the exceed purchase physicians XXXX, of these quarterly procedural at to volumes that to
base a focus strong advocates for who technology. establishing Our commercial Pure-Vu on of remains our users are
as creation As now awareness does within same thoughtfully want grows, opportunity use to sales the health To support do system. that started reach in well expand I drivers. growth, our have hospitals areas. hospitals solution to value adding Pure-Vu, both four we the shift gears our within for to in as needed anticipate our so resources our to to select XXXX sister
the disposable Let's report granted I'm new And the GI endoscopy, to are is market existing fit at clinical they utility identify for sleeve lab. another start and that innovation. in attempting lower by GI two uses gastroscope new commercial clearance source. procedures are same able during blood activity consider we've GI performed use of to will Pure-Vu Therefore, same developing new overall the been the soon as the the Upper pleased an Pure-Vu upper exciting in capital hospitals solution. our the adherent physician on XXX-k the sleeves customer using further blood perspective view This to as our obstruct same us the frequently that weeks ago, to opportunity the target sleeve and endoscopy. need enhances target GI critical new bleed and product base equipment designed a of Pure-Vu The From clots application. for physicians. treat GI be FDA Upper for our field with for Pure-Vu the
We market the a removing expands expect Upper XXX,XXX occur vortex US approximately US leveraging bleeds our improve by pulsed key cases irrigation visibility. Pure-Vu sense obstructions smart XX%. that per of by in a and with year, play to the in our addressable inpatient approximately GI can in at rate total technology, assisting which suction role these
Pure-Vu first our initiate Upper our us collaboration and case GI leverage clinical approval will FDA In users. utility terms gain evaluations of to is next to with clinical steps, that allow in demonstrate priority learnings existing to
commence world our XX in to expect who procedures. June pilot key initial of at excellence, real centers will perform We cases of approximately series an
we During of experience cases. important feedback procedural a this and UPPER will phase, different patient GI pilot across gain variety
Upper launch. We expect these learnings to a help GI inform for commercial our full plans
Now in accelerator potentially quarter, let's technology one to add-on we two to commercial our In Pure-Vu reimbursement. execution. would setting submitted serve if reimbursement inpatient CMS; applications reimbursement for for payment, as and awarded provide the fourth an the discuss which current a new
could outcomes provide through a patient the centers for complement our potential to may additional outpatient catalyst due it health the drivers, direct awarded for cancer the that is be adopt system for only payments. would pass delivers Pure-Vu procedures to an in physicians of business, first for innovative serve as which incentive coverage to coverage Securing transitional be superior the colorectal and Pure-Vu application believe screening our second through for Pure-Vu an and outpatient important course, economic pass favorable today. The technology Financial payment, if outpatient of we market.
the We're stages to of of Pure-Vu by gain executing We payers. our for the system in by expect CMS feedback initial also both on coverage applications private the end XXXX. strategy
to access process variety provider first we've top an aligning am mind firms, us our to to in The a nation's has different with to just I the our agreement we call a help date. efforts. initial and as this obtain manage partner for to services submissions a outlined well only one And that who keep to signed reimbursement. been develop this implement a of product pleased to step reimbursement payer Please report engaged there in system. review assist with of platform us is partnership outreach in program, on avenues peer reimbursement support patient as that are the external and
making While forward. to I'm we move cannot company. guarantee we're plans a terms, the this is reimbursement payment or the key our favorable progress pleased early with for priority And
in and helpful of to We compelling new cancers as generate cost, Moving our to lifetime believe cancer per Pure-Vu There of for of colorectal colonoscopy. could the sponsored the current week, journal to outcomes system clinical screening. patient current findings to care are savings of compared outpatient this driver, in the $XXX and up outlined the the the this of coverage. a quality Effectiveness Allocation for creation use that new life the our third the Resource analysis seek on data. to article of has the colorectal published Cost of Last aversion standard potential show important of care and system generation data of standard Pure-Vu be to outpatient compared efforts reimbursement value outpatient
of current This study the from evaluating to clinical bowel XXXX. last is of who we study compared outcomes investigator GI hours patients. to of we challenge the bleed We typically our XX prep The The bleeding. is with at the time Pure-Vu study is anticipate for using current this begin enroll minimal could terms this patients to having Clinic as benefits diagnosis to bowel of GI initiated and completed Cleveland the XX studies, as study In designed a end clinical the complete reported faster call, received system emergent provide our the standard during patients patients enrolling. by to prep. undergo care to in will economic much full to lower required active at currently least critical study lower XX
to as Finally, let strategic our relates thinking partnerships. reiterate me it
to several with partners. potential strategic We advance dialogue continue our
focus US, targeted in pathways for shareholders. enhance our our and our technology Our of and commercial finding US in unlock outside expand is value the regions development efforts to accelerate and the
value commercial believe and will important highly the focused our beyond. deployed potential progress. market, As criteria, business drivers will we I quarter. the and approach to we're strategic capitalize first options continue of to disciplined making to In fit in that for And over our consideration. a that their drive Andrew? call Pure-Vu and the Andrew, turn greater summary, trajectory will if for awareness results of utilization we the become review four available now to and in actionable our the financial have creation XXXX on enhance who
